2. Autophagy Apoptosis JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. Autophagy Apoptosis EGFR
  4. Corosolic acid

Corosolic acid  (Synonyms: 科罗索酸; Colosolic acid)

目录号: HY-N0280 纯度: 99.67%
COA 产品使用指南 技术支持

Corosolic acid (Colosolic acid) 是一种天然化合物，据报道具有抗肿瘤活性。Corosolic acid 可诱导癌细胞凋亡 (Apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Corosolic acid Chemical Structure

Corosolic acid Chemical Structure

CAS No. : 4547-24-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥364
In-stock
5 mg ￥350
In-stock
10 mg ￥520
In-stock
25 mg ￥840
In-stock
50 mg ￥1260
In-stock
100 mg ￥1900
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Corosolic acid:

Corosolic acid 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 1 篇科研文献

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Corosolic acid (Colosolic acid) isolated from the fruit of Cratoegus pinnatifida var. psilosa, was reported to have anticancer activity. Corosolic acid induces cancer cell apoptosis[1][2][3].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 GI50
> 100 μM
Compound: 21
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
BV-2 IC50
47.1 μM
Compound: 12
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
[PMID: 28358502]
CCRF-CEM IC50
3.27 μM
Compound: 14
Cytotoxicity against human CEM cells after 48 hrs
Cytotoxicity against human CEM cells after 48 hrs
[PMID: 20873721]
H9 EC50
4 μg/mL
Compound: 7
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
[PMID: 9748372]
H9 IC50
8 μg/mL
Compound: 7
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
[PMID: 9748372]
HCT-116 GI50
> 100 μM
Compound: 21
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
[PMID: 32345458]
HEK293 IC50
0.81 μM
Compound: 1
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
[PMID: 20100662]
HepG2 IC50
> 10 μM
Compound: 23
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 27797185]
HT-29 IC50
> 10 μM
Compound: 14
Cytotoxicity against human HT-29 cells after 48 hrs
Cytotoxicity against human HT-29 cells after 48 hrs
[PMID: 20873721]
MCF7 IC50
> 10 μM
Compound: 23
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 27797185]
MCF7 IC50
> 10 μM
Compound: 14
Cytotoxicity against human MCF7 cells after 48 hrs
Cytotoxicity against human MCF7 cells after 48 hrs
[PMID: 20873721]
MCF7 GI50
18.5 μM
Compound: Corosolic acid
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
MCF7 GI50
62 μM
Compound: 21
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 32345458]
MDA-MB-231 GI50
15.3 μM
Compound: Corosolic acid
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 28754470]
NCI-H460 IC50
> 10 μM
Compound: 14
Cytotoxicity against human NCI-H460 cells after 48 hrs
Cytotoxicity against human NCI-H460 cells after 48 hrs
[PMID: 20873721]
NCI-N87 IC50
4.4 μM
Compound: 23
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
[PMID: 27797185]
Sf21 IC50
> 40 μM
Compound: 24
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
[PMID: 31774676]
SK-OV-3 IC50
10.51 μM
Compound: 1
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
[PMID: 35500202]
SK-OV-3 IC50
26.42 μM
Compound: 1
Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)
Reversal of platinum resistance in cisplatin-resistant human SK-OV-3 cells assessed as reduction in cisplatin IC50 after 48 hrs in presence of cisplatin by SRB assay (Rvb = 28.23 microM)
[PMID: 35500202]
体外研究
(In Vitro)

Corosolic acid 对 Hep G2、A549、SNU-C4、HeLa、K-562 细胞具有细胞毒性，ED50s 为 0.4-5.0 μg/mL[1]。
Corosolic acid (0-50 μg/mL) 以剂量依赖性方式抑制 PKC 活性[1]。
Corosolic acid (0-50 μM，6-24 小时) 可诱导细胞凋亡并增加 CT-26 细胞中亚 G1 细胞群的细胞数量[3]。
Corosolic acid (20 μM，0-24 小时) 抑制 HCT116 和 SW480 细胞中 HER2/HER3 异二聚化以及 HER2 和 HER3 的磷酸化[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Corosolic acid 相关抗体:

Apoptosis Analysis[3]

Cell Line: CT-26 cells
Concentration: 25 µM
Incubation Time: 12 and 24 h
Result: Increased cleaved caspase-3 level.
Increased cells in the sub-G1 population.
Increased fluorescin-dUTP labeling DNA strand breaks.

Western Blot Analysis[5]

Cell Line: HCT116 and SW480 cells
Concentration: 20 μM
Incubation Time: 0-24 h
Result: Decreased the formation of NRG1-induced HER2/HER3 heterodimer.
Inhibited the PI3K/Akt/PDE3B but not the ERK1/2 signaling pathway.
体内研究
(In Vivo)

Corosolic acid (5、25mg/kg/天，瘤周注射，12 天) 在 CT-26 同种异体移植结肠癌小鼠模型中抑制肿瘤生长并显示出抗血管生成作用[3]。
Corosolic acid (10 和 20 mg/kg，腹腔注射，每 2 天一次) 通过激活内质网应激来抑制小鼠 PC-3 异种移植模型中的肿瘤生长[4]。
Corosolic acid (10 mg/kg/d，在饮食中补充，8 周) 可抑制脂肪组织炎症，并通过激活 AMPK 改善高脂喂养小鼠的胰岛素抵抗[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CT-26 allograft colon carcinoma mice model[3]
Dosage: 5, 25 mg/kg/day
Administration: Peritumor injection, 12 days
Result: Reduced the tumor weight to 76.2% and 53.8% of the control group.
Reduced blood and lymphatic vessel densities.
Animal Model: high-fat fed mice[6]
Dosage: 10 mg/kg/day
Administration: Supplemented in diet, 8 weeks
Result: Inhibited hyperlipidemia, Improved insulin sensitivity and glucose intolerance.
Inhibited inflammation in adipose tissues.
Inhibited macrophage infiltrations into adipose tissue.
分子量

472.70

Formula

C30H48O4
CAS 号
性状

固体

颜色

White to off-white

中文名称

科罗索酸
结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验： 

DMSO 中的溶解度 : 25 mg/mL (52.89 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1155 mL 10.5775 mL 21.1551 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.75 mg/mL (5.82 mM); 澄清溶液

    此方案可获得 ≥ 2.75 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (5.29 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.67%

COA (290 KB) HNMR (296 KB) RP-HPLC (226 KB) MS (72 KB)

产品使用指南 (1538 KB)
参考文献

Corosolic acid 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1155 mL 10.5775 mL 21.1551 mL 52.8877 mL
5 mM 0.4231 mL 2.1155 mL 4.2310 mL 10.5775 mL
10 mM 0.2116 mL 1.0578 mL 2.1155 mL 5.2888 mL
15 mM 0.1410 mL 0.7052 mL 1.4103 mL 3.5258 mL
20 mM 0.1058 mL 0.5289 mL 1.0578 mL 2.6444 mL
25 mM 0.0846 mL 0.4231 mL 0.8462 mL 2.1155 mL
30 mM 0.0705 mL 0.3526 mL 0.7052 mL 1.7629 mL
40 mM 0.0529 mL 0.2644 mL 0.5289 mL 1.3222 mL
50 mM 0.0423 mL 0.2116 mL 0.4231 mL 1.0578 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Corosolic acid4547-24-4Colosolic acid科罗索酸AutophagyApoptosisEGFREpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Corosolic acid
目录号：
HY-N0280
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z